Morgan Stanley
BRNS

Morgan Stanley’s Barinthus Biotherapeutics BRNS Stock Holding History

Morgan Stanley’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.26K Sell
2,210
-1,196
-35% -$788 ﹤0.01% 7398
2025
Q4 		$2.38K Sell
3,406
-1,536
-31% -$1.53K ﹤0.01% 7211
2025
Q3 		$6.18K Buy
4,942
+90
+2% +$113 ﹤0.01% 7037
2025
Q2 		$4.51K Buy
4,852
+3,981
+457% +$3.48K ﹤0.01% 7065
2025
Q1 		$847 Sell
871
-7,150
-89% -$7.34K ﹤0.01% 7305
2024
Q4 		$9.69K Sell
8,021
-3,962
-33% -$4.61K ﹤0.01% 6815
2024
Q3 		$14.3K Buy
11,983
+3,110
+35% +$4.17K ﹤0.01% 6609
2024
Q2 		$12.4K Sell
8,873
-3,989
-31% -$9.01K ﹤0.01% 6602
2024
Q1 		$30.6K Sell
12,862
-20,072
-61% -$56.7K ﹤0.01% 6372
2023
Q4 		$122K Buy
32,934
+11,719
+55% +$39.6K ﹤0.01% 6097
2023
Q3 		$65.6K Buy
21,215
+5,768
+37% +$12.4K ﹤0.01% 6050
2023
Q2 		$31.8K Sell
15,447
-53,350
-78% -$126K ﹤0.01% 6384
2023
Q1 		$154K Buy
68,797
+56,982
+482% +$159K ﹤0.01% 5827
2022
Q4 		$27.8K Sell
11,815
-753
-6% -$1.92K ﹤0.01% 6546
2022
Q3 		$40K Sell
12,568
-1,241
-9% -$5.27K ﹤0.01% 6498
2022
Q2 		$61K Buy
13,809
+4,511
+49% +$21.7K ﹤0.01% 6519
2022
Q1 		$48K Sell
9,298
-333
-3% -$2.68K ﹤0.01% 6719
2021
Q4 		$107K Sell
9,631
-14,443
-60% -$182K ﹤0.01% 6399
2021
Q3 		$379K Buy
24,074
+7,193
+43% +$109K ﹤0.01% 5659
2021
Q2 		$284K Buy
+16,881
New +$250K ﹤0.01% 5844

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Morgan Stanley's BRNS Position: Q1 2026 in Review

Morgan Stanley reduced its Barinthus Biotherapeutics (BRNS) stake by 35% in Q1 2026, selling an estimated $788 and leaving 2,210 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #7398.

Morgan Stanley first reported a position in BRNS in Q2 2021 and has held it in 20 quarters since. The position peaked at $379K in Q3 2021. 14 funds tracked by Wall St. Rank hold BRNS as of Q1 2026.

  • Morgan Stanley held 2,210 shares of Barinthus Biotherapeutics worth $1.26K as of Q1 2026.
  • Morgan Stanley sold 1,196 Barinthus Biotherapeutics shares in Q1 2026, an estimated $788.
  • Barinthus Biotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7398 holding.
  • Morgan Stanley first reported a position in Barinthus Biotherapeutics in Q2 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Barinthus Biotherapeutics position peaked at $379K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.